ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE (enalapril maleate; hydrochlorothiazide) by Teva is mechanism of action enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension. First approved in 2004.
Drug data last refreshed 19h ago
Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates…
Worked on ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.